The spectrum of drug susceptibility of slow-growing nontuberculous mycobacteria (MAC, M. kansasii, M. xenopi) Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017
Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections Source: Eur Respir J , 49 (3) 1601969; DOI: 10.1183/13993003.01969-2016 Year: 2017
Clinical relevance of differentiation between Mycobacterium avium and M. intracellulare in M. avium complex pulmonary disease in Croatia Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
In vitro susceptibility of M. avium against protionamide Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Pulmonary diseases caused by non-tuberculous mycobacteria Source: Eur Respir Mon 2012; 58: 25-37 Year: 2012
Invasive Mycobacterium avium intracellulare infection Source: Eur Respir J 2006; 28: Suppl. 50, 312s Year: 2006
Amikacin exposure and susceptibility of macrolide-resistant Mycobacterium abscessus Source: ERJ Open Res, 5 (2) 00154-2018; 10.1183/23120541.00154-2018 Year: 2019
Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients Source: Eur Respir J 2013; 41: 1101-1106 Year: 2013
Characterization of drug susceptibility of nontuberculous mycobacteria of M.chelonae and M.fortuitum complexes. Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018
Genotyping of human Mycobacterium kansasii isolates from Poland. Source: International Congress 2017 – Microbiology and laboratory techniques to monitor NTM infections Year: 2017
Isolation of M. abscessus from patients with M. avium complex (MAC) lung disease Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections Year: 2013
LATE-BREAKING ABSTRACT: Poor outcome following lung transplantation in CF patients infected with mycobacterium abscessus appears to be associated with two genetic clusters of mycobacterium abscessus subspecies abscessus Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections Source: Eur Respir J, 49 (5) 1700083; 10.1183/13993003.00083-2017 Year: 2017
Infection of the respiratory mucosa by Mycobacterium avium complex (MAC), Mycobacterium tuberculosis (MTB) and Mycobacterium smegmatis (MS) Source: Eur Respir J 2001; 18: Suppl. 33, 308s Year: 2001
Clinical relevance of Mycobacterium malmoense isolation in the Netherlands Source: Eur Respir J 2009; 34: 926-931 Year: 2009
Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022
Long-term survival of patients with mycobacterium avium- intracellulare complex pulmonary disease (MAC-PD) Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008
Mycobacterium abscessus activates cross-resistance following antibiotic exposure Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Mycobacterium tuberculosis resistance Source: Eur Respir J 2002; 20: Suppl. 38, 360s Year: 2002
Recurrent laboratory pseudo-outbreaks of Mycobacterium intracellulare Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008